111 Inc regains Nasdaq compliance with share price

SHANGHAI - 111, Inc. (NASDAQ: YI), a healthcare platform company in China, has regained compliance with the Nasdaq’s minimum share price requirement. The Nasdaq confirmed on February 10, 2025, that for ten consecutive business days, from January 24 to February 7, 2025, the closing bid price of the company’s American Depositary Shares was at or above $1.00. This achievement aligns with Nasdaq Listing Rule 5450(a)(1), which stipulates the minimum bid price condition. The stock, currently trading at $7.18, has shown strong momentum with a 10.8% gain over the past week, according to InvestingPro data.

The notification from Nasdaq marks the closure of the compliance matter for 111, Inc., which operates an integrated online and offline healthcare platform. The platform includes an online retail pharmacy, a virtual pharmacy network, online healthcare services, and a one-stop shop for pharmacies to source pharmaceutical products. With a market capitalization of $61.5 million and gross profit margins of 3.16%, the company has established itself as a notable player in China’s healthcare sector.

The company’s recent compliance success reflects its ongoing efforts to meet Nasdaq’s stringent listing criteria. While this development is a positive step for 111, Inc., the company’s forward-looking statements in the press release caution about inherent risks and uncertainties that could impact future operations and market conditions. These include regulatory challenges, competition in the health and wellness market, growth management, profitability, and maintaining Nasdaq listing standards. InvestingPro analysis suggests the stock is currently undervalued, with analysts predicting profitability this year. For deeper insights into 111, Inc.’s valuation and 14 additional ProTips, consider accessing the comprehensive Pro Research Report available on InvestingPro.

Investors are reminded that forward-looking statements are based on the company’s current expectations and are subject to change due to various factors, many of which are beyond the company’s control. The company has emphasized its commitment to adhere to regulatory requirements and to continue providing digital healthcare services to consumers and pharmacies in China.

This article is based on a press release statement and aims to provide investors with a concise update on 111, Inc.’s current compliance status with the Nasdaq.

In other recent news, 111, Inc., a retail drugstore chain, has been making significant strides in its operations. The company recently announced it has regained compliance with NASDAQ’s listing requirements, a development that may boost investor confidence in its governance and financial health. In addition, 111, Inc. disclosed a modification to its American Depositary Share (ADS) ratio in a recent filing with the Securities and Exchange Commission, although the specific details of the ratio change were not disclosed.

In the midst of these developments, the company has managed to maintain operational profitability for the third consecutive quarter in Q3 2024, even amidst a challenging macroeconomic landscape. The company’s net revenues held steady at RMB 3.6 billion, while gross segment profit saw a notable increase of 10.5%, reaching RMB 210.6 million. A significant reduction in operating expenses contributed to this performance.

These recent developments underscore 111, Inc.’s resilience in the face of market challenges. The company’s focus on digital transformation and operational efficiency, coupled with its commitment to regulatory compliance, suggests a strategic approach to navigating the competitive retail drugstore market. It’s worth noting that while these updates provide valuable insights into the company’s current status, investors may look forward to future announcements or filings for more detailed updates on the company’s operations and financials.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.